Atopic dermatitis (AD) is predominantly a disease of infancy and childhood, yet there are few studies investigating the immune profile of the skin in this population. Thus, relevant AD biomarkers are largely lacking, especially for stratification of the disease’s severity, progression, and response to therapy. This gap is especially relevant as new medications for AD become available for the pediatric group, necessitating decision-making about which children will benefit. Some of the limitations for such data collection are related to the difficulty with obtaining samples in a research setting from infants and children, in whom phlebotomy and skin biopsies can cause health care–induced trauma and anxiety for both guardians and their children.1 Families will often opt out of biopsies in clinical trials or not participate even when minimally invasive procedures are incorporated. Better noninvasive techniques are needed to obtain biomarkers for more robust research.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Castelo-Soccio L. Stripping Away Barriers to Find Relevant Skin Biomarkers for Pediatric Atopic Dermatitis. JAMA Dermatol. 2019;155(12):1342–1343. doi:10.1001/jamadermatol.2019.2792
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: